CureDuchenne congratulates Pfizer on their progress to a Phase III clinical trial for #PF-06939926, its AAV9 mini-dystrophin gene therapy for Duchenne muscular dystrophy. We’re grateful to Pfizer for their dedication […]
CureDuchenne has wrapped up our 2019 Webinar Series. We are committed to delivering the most up-to-date and accurate information to the Duchenne Community and are honored to have had the […]
AUTHOR: Romina Foster-Bonds (View Spanish Version Below) CureDuchenne has made a significant commitment to develop and maintain a biobank dedicated to Duchenne muscular dystrophy — the CureDuchenne Biobank. The CureDuchenne […]
The last day 24th International Annual Congress of the World Muscle Society (WMS) opened with a talk touching on a growing field in neuromuscular disorders – the use of digital […]
Many therapies being developed for Duchenne muscular dystrophy, including gene therapies, gene editing, and some exon-skipping approaches, rely on use of a virus to get the therapeutic components inside of […]
Even though it’s a conference of the World Muscle Society, the presentations on Thursday morning focused on the disease processes happening in parts of the body other than muscle. This […]
Today was the first full day of research talks and posters at the 24th International Annual Congress of the World Muscle Society (WMS). It’s a busy meeting, with nearly 1,000 […]
Greetings from Copenhagen, Denmark, where several members of the CureDuchenne team are attending the 24th International Annual Congress of the World Muscle Society (WMS). This is the largest annual international […]
Today’s FDA disapproval of Sarepta’s Vyondys 53 is disheartening, but a true example of just how difficult and costly the drug development process is. We appreciate Sarepta’s efforts and dedication […]
